Cookson Peirce & Co. Inc. Has $14.44 Million Holdings in argenx SE (NASDAQ:ARGX)

Cookson Peirce & Co. Inc. decreased its holdings in argenx SE (NASDAQ:ARGX) by 0.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,483 shares of the company’s stock after selling 83 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in argenx were worth $14,442,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARGX. Whipplewood Advisors LLC bought a new position in shares of argenx in the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC lifted its stake in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in argenx during the 4th quarter worth $66,000. Finally, Nkcfo LLC bought a new stake in shares of argenx in the 4th quarter worth $68,000. 60.32% of the stock is owned by institutional investors.

argenx Stock Down 0.2 %

NASDAQ ARGX opened at $621.25 on Wednesday. The company’s 50 day moving average is $642.51 and its 200-day moving average is $591.91. The firm has a market cap of $37.75 billion, a P/E ratio of -705.97 and a beta of 0.58. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities analysts expect that argenx SE will post 3.13 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ARGX. Evercore ISI raised their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Robert W. Baird boosted their target price on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research note on Tuesday. JMP Securities upped their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target on the stock in a report on Tuesday, November 12th. Finally, William Blair restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and a consensus target price of $662.83.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.